SHASUNPHAR

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on August 06, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Nomination & Remuneration Committee of the Company at its meeting held on August 06, 2014 had granted 2,23,000 stock options under Employee Stock Option Plan 2012 to the employees exercisable into same number of Equity shares of the Company.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the Voting Result of the Annual General Meeting of the Company held August 06, 2014 as per Clause 35A of the Listing Agreement.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the following changes in the Board of Directors of the company with effect from August 06, 2014:(1). Mr. M. Mohan, Whole time Director- EHS, has resigned from the Board.(2) Dr. Arun Chandra Karmakar appointed as Director- Operations & EHS. The changes have been recorded and approved at the Board of Directors' Meeting held on August 06, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 06, 2014, titled "Shasun Pharmaceuticals Limited announces Quarter 1 FY 15 results".

Shasun Pharmaceuticals Limited has submitted to the exchange the consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Devendra Estates Pvt Ltd has submitted to the Exchange vide letter dated July 16, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 08, 2014, titled "Sucessful completion of US FDA and Mexican COFEPRIS inspection".

Shasun Pharmaceuticals Limited has submitted to the Exchange vide letter dated June 19, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Morgan Stanley Asia (Singapore) Pte has submitted to the Exchange, vide letter dated June 19, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sequent Scientific Limited has submitted to the Exchange, vide letter dated June 03, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Sequent Scientific Limited has submitted to the Exchange vide letter dated June 03, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Company has fixed Book Closure from August 1, 2014 to August 6, 2014 (both days inclusive) for the purpose of dividend. Further, the Annual General Meeting of the Company will be held on August 06, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Dividend payment will be between August 11, 2014 and August 16, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 30, 2014 has recommended a dividend of 50% (Rs.1.00 per share) on the equity shares of face value of Rs.2/- each, subject to shareholders approval at ensuing Annual General Meeting.

Shasun Pharmaceuticals Limited has informed the Exchange regarding outcome of board meeting held on May 30, 2014.

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Shasun Pharmaceuticals Limited has submitted to the Exchange vide letter dated May 22, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(3) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a proceeding of Extra Ordinary General Meeting held on May 21, 2014 under Clause 35A.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the outcome of Extraordinary General Meeting of the Company held on May 21, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that the since the Board has not declared dividend, the record date of May 28, 2014 should be treated as cancelled.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 21, 2014 has decided not to declare any interim dividend for the financial year 2013-14.

Sundaram Asset Management Co Ltd has submitted to the Exchange vide letter dated May 20, 2014 a copy of Disclosure in terms of Regulation 29 (2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange that the Company has fixed Record Date as May 28, 2014 for the purpose of of interim dividend.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 05, 2014, titled "Acquisition of Global rights of Ibuprofen 12 Hr Extended Release OTC & Nuprin brand"

D Sajjan has submitted to the Exchange vide letter dated April 23, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of Extraordinary General Meeting scheduled to be held on May 21, 2014.

Shasun Pharmaceuticals Limited has informed the Exchange that there was a fire accident at Ibuprofen IP Grade packing section in API facility at Pondicherry around 2.30 a.m. on April 27, 2014. This is an isolated packing section from the main production block and other grades packing section. There was no impact to the other manufacturing operations, product supplies and no major damage to the facility. There has not been human casualty or injuries. The facility is fully covered with insurance.

Shasun Pharmaceuticals Limited has informed the Exchange regarding the Outcome of Board Meeting of the Company held on April 23, 2014.

D Jitesh has submitted to the Exchange, vide letter dated April 12, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange vide letter dated April 16, 2014 regarding "Update on Joint Venture- Alvira Animal Health Limited".

Shasun Pharmaceuticals Limited has informed the Exchange regarding Joint venture agreement with Sequent Scientific Limited.

D Sjjan has submitted to the Exchange vide letter dated March 05, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange vide letter dated March 07, 2014, titled"Joint Venture Agreement".

V Leela has submitted to the Exchange vide letter dated March 03, 2014 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-dec-2013.

Shasun Pharmaceuticals Limited has informed the Exchange Vide letter dated January 23, 2014 regarding Declaration of Postal Ballot-results

Shasun Pharmaceuticals Limited has submitted to the Exchange Notice of Postal Ballot dated December 12, 2013.

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on December 12, 2013 decided to sell/ transfer the Company's unit situated at JN Pharma City, Vizag to a joint venture or any other person in any manner as the Board may consider appropriate subject to the approval of the shareholders. The Board has decided to obtain Shareholders approval by way of Postal Ballot.

Shasun Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-sep-2013.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated October 24, 2013, titled "Successful completion of MHRA EU Inspection".

Shasun Pharmaceuticals Limited has submitted to the Exchange vide letter dated October 21, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Easyaccess Financial Services Limited has submitted to the Exchange vide letter dated October 18, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 30, 2013, titled "Successful completion of MHRA EU Inspection".

Shasun Pharmaceuticals Limited has submitted to the Exchange the details of voting results as per clause 35A of listing agreement alongwith copy of minutes of Annual General Meeting held on August 2, 2013.

Shasun Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended June 30,2013.

Shasun Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2013 titled "Successful completion of US FDA and Brazilian ANVISA inspection".

Shasun Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on July 13, 2013, had reviewed the operations of the Company and had taken a decision to set up new joint venture company at Vizag to develop, manufacture and sell of veterinary products inclusive of both in API and Formulations in the global market with collaboration with SeQuent Scientific Ltd. Further, the Company has submitted a copy of Press Release dated July 13, 2013, titled "Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd announce Joint Venture to Create Leading A

Shasun Pharmaceuticals Limited has submitted to the Exchange, vide letter dated June 21, 2013 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.